原标题：美国硅谷生物技术公司 Flow Pharma 荣获美中杰出贡献奖！

Flow Pharma is a biotechnology company headquarter in San Francisco Bay Area. Founded by several famous executives Reid Rubsamen and Jack Lloyd, Flow Pharma aims to tackle one of the most difficult challenges of our time – treating cancer. Since 2009, Flow Pharma developed highly optimized vaccine delivery platform called SEAPAC, that can be used to treat, or even cure a wide variety of diseases, including viral diseases and cancer. In addition, Flow Pharma partnered with several Chinese, European and American companies and developed a highly accurate neoantigen selection system that can identify and validate the targets on cancer cells within 3 weeks, and manufacture and deliver the personalized cancer vaccine in another week.

Flow Pharma 是一家总部位于旧金山湾区的生物技术公司。Flow Pharma 由两位成功的连续创业者 Reid Rubsamen 和 Jack Lloyd 创立，旨在解决我们这个时代最困难的挑战之一 治疗癌症。自2009年以来，Flow Pharma 开发了一个高度优化的疫苗技术平台，叫做 SEAPAC。该技术平台可用于治疗甚至治愈各种疾病，包括病毒性疾病和癌症。此外，Flow Pharma 与多家中国，欧洲和美国公司合作，开发了一种高度准确的新抗原选择系统，可在3.5周内识别和验证癌细胞的靶标，并以这些靶标为基础在一周内制造出完全个性化的癌症疫苗，并把疫苗输送给患者。

In addition, Flow Pharma’s technology bears the most important hallmarks of a groundbreaking cancer treatment technologies: safe, effective, low cost, and broadly applicable. No other immunotherapies in the world can compete with Flow Pharma on all 4 fronts. In fact, Flow Pharma’s technology excels in every single category.

此外，Flow Pharma 的技术具有突破性癌症治疗技术的最重要标志：安全，有效，低成本和广泛应用。世界上没有任何其他免疫疗法可以在所有四个方面与 Flow Pharma 竞争。事实上，Flow Pharma 的技术在每一个类别中都表现出色。

Flow Pharma’s technology has been tested on a mouse Ebola model and achieved sterling results: the vaccinated mice was protected from morbidity and mortality 100%; in comparison, 60-80% of unvaccinated mice died of the viral infection; even those that survived was severely sick for several days before recovering.

Flow Pharma 的技术已经在小鼠埃博拉模型上进行了测试并获得了出色结果：接种疫苗的小鼠发病率和死亡率均为0; 相比之下，60-80％未接种疫苗的小鼠死于病毒感染； 而那些幸存下来小鼠在恢复之前体重锐减。

With the help from Dr. Lu Wang, Flow Pharma started a joint venture in China in 2017, Hefei Sageland Biotechnology Co Ltd. Within a year Flow Pharma accomplished several milestones : 1) In collaboration with the Chinese Academy of Medical Sciences, Flow Pharma designed two clinical protocols aiming to put a cervical cancer vaccine to test; 2) Flow Pharma received investments from Hefei Button Capital and BGI’s Miracle Light Accelerator; 3) Flow Pharma identified a companion diagnostics company and a gene sequencing company in China; 4) Flow Pharma established a manufacturing and R D facility in Nanjing, China that’s capable of manufacturing a medical device that can prevent surgical site infection; 5) Last but least, Flow Pharma participated Shanghai Yangpu District’s Star of Startups competition and won the first place in the Silicon Valley Region.

在王路博士的帮助下，Flow Pharma 于2017年在中国成立合资企业，合肥萨其兰生物技术有限公司。此后一年内，Flow Pharma 完成了几个里程碑：1）与中国医学科学院合作，Flow Pharma 设计了两个 旨在对宫颈癌疫苗进行检测的临床方案; 2） Flow Pharma 从合肥Button Capital 和华大基金的蓝色彩虹加速器获得投资; 3）Flow Pharma 在中国找到了一家伴随诊断公司和一家基因测序公司; 4）Flow Pharma 在中国南京建立了一个制造和研发设施，能够制造一款可以防止手术部位感染的医疗设备; 5）最后，Flow Pharma 参加了上海杨浦区的创业之星竞赛，并在硅谷地区获得了第一名。

Flow Pharma sees its work in China as an important pillar of its global operation. The company deeply appreciate China’s world-class medical facility and excellent clinical research staff and operation. In 2020 Flow Pharma will initiate a Phase II clinical trial in China, with its FlowVAX HPV cervical lesion and cervical cancer vaccine. Upon approval, this vaccine is expected to help hundreds of thousands of patients per year.

Flow Pharma 将其在中国的工作视为其全球运营的重要支柱。公司深深体会到中国世界一流的医疗设施和优秀的临床研究人员给公司带来了巨大的市场和社会价值。2020年，Flow Pharma将在中国启动一项 FlowVAX HPV 宫颈病变和宫颈癌疫苗的II期临床试验。获国家药监局批准后，该疫苗每年可帮助上百万中国患者恢复健康。

2019年09月14日，Flow Pharma团队将亲自出席《中美建交40周年庆祝活动暨第五届美中杰出贡献奖颁奖盛典、中美投资高峰论坛》并现场路演，敬请期待！返回搜狐，查看更多

责任编辑：